Companies › TYK Medicines
2 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TY-9591 EGFR inhibitor | – | Phase 3 | NSCLC | Dec 2027 |
| TYK-00540 | – | Phase 1 | HR-positive, HER2-negative Advanced Breast Cancer; Locally Advanced or Metastatic Solid Tumors | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06950086 | TYK-00540 | Phase 1 | HR-positive, HER2-negative Advanced Breast Cancer | Oncology | Nov 2026 |
| NCT06246071 | TYK-00540 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Dec 2026 |
| NCT05382728 | TY-9591 | Phase 3 | NSCLC | Oncology | Dec 2027 |
| NCT05948813 | TY-9591 | Phase 2 | NSCLC | Oncology | Mar 2030 |
No annotated target.
–
Clarity Pharmaceuticals Impact Therapeutics TransThera Sciences (Nanjing) InxMed (Shanghai) Advenchen Laboratories
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.